Cited 0 times in

Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.

Authors
 Kim H.S. ; Hong M.H. ; Rha S.Y. ; Bang Y.-J. ; Lee S.-H. ; Koh Y. ; Chung H.C. ; Jeung H.C. ; Ahn J.-B. ; Shin S.-J. ; Kim K.b 
Citation
 Oncology, Vol.80(5-6) : 395~405, 2011 
Journal Title
 Oncology 
ISSN
 0030-2414 
Issue Date
2011
Abstract
OBJECTIVE: We aimed to describe the efficacy and safety of sunitinib in unselected Korean advanced renal cell carcinoma (RCC) patients. PATIENTS AND METHODS: From November 2005 to August 2008, 132 histologically confirmed advanced RCC patients (100 in the global expanded access program) were enrolled. Response and toxicity were assessed regularly according to the protocol. RESULTS: Within this population, 82.6% had clear cell RCC, and 28.8% were treatment naïve. Patients received a median of 5 cycles of sunitinib (range 1-30), and the mean relative dose intensity was 82.0 ± 14.20 (SD). The progression-free survival (PFS) and overall survival rates were 8.2 and 23.1 months, respectively. For the 130 evaluable patients, the objective response rate was 34.1% (n = 45); 44.7% (n = 59) exhibited stable disease. Reasons for discontinuation were disease progression (75.0%) and toxicity (7.6%). The most frequent adverse events were thrombocytopenia (75.0%), neutropenia (70.5%), and anemia (69.7%). Low body surface area (OR = 4.2, 95% CI 1.2-13.8, p = 0.02) and previously treated status (OR = 3.1, 95% CI 1.3-7.4, p = 0.01) were highly predictive of grade 3-4 toxicities. Based on these findings, a nomogram predicting the probability of 12-month PFS was constructed, giving a concordance index of 0.675. CONCLUSIONS: Despite the different toxicity profiles, maintaining adequate dose modifications and a careful follow-up enables comparable treatment outcomes for unselected Korean advanced RCC patients
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/93652
DOI
10.1159/000330361
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
1. 연구논문 > 5. Research Institutes > Oral Cancer Research Institute
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://www.karger.com/Article/FullText/330361
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse